Outcomes for 16 patients treated with 19-28z CAR EBV-VSTs
| Patient . | Disease . | Target T-cell dose . | LDC . | Pretreatment disease burden∗ . | Initial response . | Time to death/last follow-up (mo) . |
|---|---|---|---|---|---|---|
| 1 | B-ALL | 1 × 106 T cells per kg (actual, 0.8 × 106 T cells per kg) | Flu 25 mg/m2 × 5 (C1) | Morphologic disease | Morphologic disease | 6.7 |
| 2 | B-ALL | 1 × 106 T cells per kg (actual, 0.9 × 106 T cells per kg) | Flu 25 mg/m2 × 5 | Morphologic disease | Morphologic disease | 4.2 |
| 3 | B-ALL | 1 × 106 T cells per kg (actual, 0.8 × 106 T cells per kg) | Flu 25 mg/m2 × 5 (C1); Cy 1800 mg/m2 × 1 (C2 and C3) | MRD+/CR | N/E | 135+ |
| 4 | NHL | 1 × 106 T cells per kg (actual, 0.6 × 106 T cells per kg) | Flu 20 mg/m2 × 4; clofarabine 20 mg/m2 × 4 (2 wk prior) | MRD+/CR | N/E | 123+ |
| 5 | B-ALL | 3 × 106 T cells per kg (actual: 2.2 × 106 T cells per kg) | Cy 900 mg/m2 × 2 | MRD+/CR | N/E | 21.7 |
| 6 | CLL | 3 × 106 T cells per kg (actual, 3.7 × 106 T cells per kg) | Cy 900 mg/m2 × 1; Flu 25 mg/m2 × 3 | MRD+/CR | MRD+/CR | 80.3+ |
| 7 | B-ALL | 1 × 107 T cells per kg (actual, 7.5 × 106 T cells per kg) | Clofarabine 40 mg/m2 × 4; Flu 25 mg/m2 × 4 | Morphologic disease | Morphologic disease | 8.1 |
| 8 | B-ALL | 1 × 106 T cells per kg (actual, 0.8 × 106 T cells per kg) | Cy 500 mg/m2 × 2; Flu 30 mg/m2 × 4 | MRD+/CR | MRD–/CR | 32.2+ |
| 9 | NHL | 3 × 106 T cells per kg (actual, 3.2 × 106 T cells per kg) | BEAM | PR | CR | 88.1+ |
| 10 | NHL | 3 × 106 T cells per kg (actual, 2.4 × 106 T cells per kg) | BEAM | PR | CR | 74.6+ |
| 11 | NHL | 3 × 106 T cells per kg (actual, 2.7 × 106 T cells per kg) | BEAM | PR | CR | 53.3+ |
| 12 | NHL | 3×106 T cells per kg (actual, 8.6×106) | BEAM | PR | CR | 39.8+ |
| 13 | NHL | 3 × 106 T cells per kg (actual, 2.8 × 106 T cells per kg) | BEAM | PR | SD | 35.1+ |
| 14 | NHL | 3 × 106 T cells per kg (actual, 3.4 × 106 T cells per kg) | BEAM | PR | CR | 30.4+ |
| 15 | NHL | 3 × 106 T cells per kg (actual, 4.0×106 T cells per kg) | Ritux/Flu/Cy/TBI (200 cGy) | CR | PD | 30.3+ |
| 16 | NHL | 3 × 106 T cells per kg (actual, 3.9 × 106 T cells per kg) | Flu/Mel | PR | CR | 27.7+ |
| Patient . | Disease . | Target T-cell dose . | LDC . | Pretreatment disease burden∗ . | Initial response . | Time to death/last follow-up (mo) . |
|---|---|---|---|---|---|---|
| 1 | B-ALL | 1 × 106 T cells per kg (actual, 0.8 × 106 T cells per kg) | Flu 25 mg/m2 × 5 (C1) | Morphologic disease | Morphologic disease | 6.7 |
| 2 | B-ALL | 1 × 106 T cells per kg (actual, 0.9 × 106 T cells per kg) | Flu 25 mg/m2 × 5 | Morphologic disease | Morphologic disease | 4.2 |
| 3 | B-ALL | 1 × 106 T cells per kg (actual, 0.8 × 106 T cells per kg) | Flu 25 mg/m2 × 5 (C1); Cy 1800 mg/m2 × 1 (C2 and C3) | MRD+/CR | N/E | 135+ |
| 4 | NHL | 1 × 106 T cells per kg (actual, 0.6 × 106 T cells per kg) | Flu 20 mg/m2 × 4; clofarabine 20 mg/m2 × 4 (2 wk prior) | MRD+/CR | N/E | 123+ |
| 5 | B-ALL | 3 × 106 T cells per kg (actual: 2.2 × 106 T cells per kg) | Cy 900 mg/m2 × 2 | MRD+/CR | N/E | 21.7 |
| 6 | CLL | 3 × 106 T cells per kg (actual, 3.7 × 106 T cells per kg) | Cy 900 mg/m2 × 1; Flu 25 mg/m2 × 3 | MRD+/CR | MRD+/CR | 80.3+ |
| 7 | B-ALL | 1 × 107 T cells per kg (actual, 7.5 × 106 T cells per kg) | Clofarabine 40 mg/m2 × 4; Flu 25 mg/m2 × 4 | Morphologic disease | Morphologic disease | 8.1 |
| 8 | B-ALL | 1 × 106 T cells per kg (actual, 0.8 × 106 T cells per kg) | Cy 500 mg/m2 × 2; Flu 30 mg/m2 × 4 | MRD+/CR | MRD–/CR | 32.2+ |
| 9 | NHL | 3 × 106 T cells per kg (actual, 3.2 × 106 T cells per kg) | BEAM | PR | CR | 88.1+ |
| 10 | NHL | 3 × 106 T cells per kg (actual, 2.4 × 106 T cells per kg) | BEAM | PR | CR | 74.6+ |
| 11 | NHL | 3 × 106 T cells per kg (actual, 2.7 × 106 T cells per kg) | BEAM | PR | CR | 53.3+ |
| 12 | NHL | 3×106 T cells per kg (actual, 8.6×106) | BEAM | PR | CR | 39.8+ |
| 13 | NHL | 3 × 106 T cells per kg (actual, 2.8 × 106 T cells per kg) | BEAM | PR | SD | 35.1+ |
| 14 | NHL | 3 × 106 T cells per kg (actual, 3.4 × 106 T cells per kg) | BEAM | PR | CR | 30.4+ |
| 15 | NHL | 3 × 106 T cells per kg (actual, 4.0×106 T cells per kg) | Ritux/Flu/Cy/TBI (200 cGy) | CR | PD | 30.3+ |
| 16 | NHL | 3 × 106 T cells per kg (actual, 3.9 × 106 T cells per kg) | Flu/Mel | PR | CR | 27.7+ |
BEAM, carmustine, etoposide, cytarabine, melphalan; C1/2/3, cycle 1/2/3; Cy, cyclophosphamide; Flu, fludarabine; LDC, lymphodepleting chemotherapy; Mel, melphalan; N/E, not evaluable; PD, progressive disease; Ritux, rituximab; SD, stable disease; TBI: total body irradiation.
Disease burden evaluation is before BMT conditioning for cohorts 2 and 3.